ClinicaliQ Trial Snapshot
- A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07759245.
- Treatment being tested: Brenipatide (LY3537031), a novel therapeutic agent, is being evaluated at multiple dose levels versus placebo to assess safety and efficacy in adults with moderate-to-severe COPD.
- Patient eligibility overview: The trial enrolls adult participants with confirmed moderate-to-severe COPD, representing a significant proportion of the COPD population who currently have limited therapeutic options beyond standard care.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.
Eligibility Snapshot
- : * Have a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD), at least 12 months prior to screening who meet the following criteria: * Current or former smokers with a smoking history of greater than or equal to (≥) 10 pack-years * Moderate-to-severe COPD (post-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV₁)/forced vital capacity (FVC) less than (
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.